Payment overview · 2025
General Payments
$909.76
49 reported records · 9 companies
Healthcare provider profile · identity verified
Jamii Johnson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAFAYETTE, TN · NPI 1275888992
Verified facts
What the public records show
CMS Open Payments records show Jamii Johnson, M.D. received $909.76 in general payments during 2025 across 49 reported records.
Vanda Pharmaceuticals Inc. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $300.69 | 33.0% | 23 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $192.53 | 21.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $187.98 | 20.7% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.48 | 10.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.58 | 3.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.44 | 3.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.38 | 3.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.31 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.37 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $886.02 | 47 |
| Education | $23.74 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $300.69 | 23 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $192.53 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $187.98 | 6 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $118.04 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
122 | 25 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 304 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 65 |
| Omeprazole | Omeprazole | 160 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 38 |
| Potassium Chloride | Potassium Chloride | 148 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 37 |
| Lisinopril | Lisinopril | 126 | 32 |
| Entresto | Sacubitril/Valsartan | 122 | 25 |
| Furosemide | Furosemide | 121 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 23 |
| Mounjaro | Tirzepatide | 109 | 17 |
| Montelukast Sodium | Montelukast Sodium | 97 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 95 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 31 |
| Pregabalin | Pregabalin | 87 | 19 |
| Vraylar | Cariprazine Hcl | 82 | 14 |
| Trazodone Hcl | Trazodone Hcl | 81 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 18 |
| Prednisone | Prednisone | 79 | 54 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 75 | 12 |
| Meloxicam | Meloxicam | 75 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 21 |
| Carvedilol | Carvedilol | 69 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 16 |
| Famotidine | Famotidine | 67 | 13 |
| Simvastatin | Simvastatin | 67 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 14 |
| Losartan Potassium | Losartan Potassium | 58 | 17 |
| Topiramate | Topiramate | 58 | 17 |
| Azithromycin | Azithromycin | 56 | 41 |
| Promethazine Hcl | Promethazine Hcl | 56 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 12 |
| Baclofen | Baclofen | 55 | suppressed |
| Clonazepam | Clonazepam | 54 | 12 |
| Tramadol Hcl | Tramadol Hcl | 54 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 16 |
| Eliquis | Apixaban | 49 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 33 |
| Linzess | Linaclotide | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 13 |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 12 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 33 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 20 |
| Clonidine Hcl | Clonidine Hcl | 31 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Estradiol | Estradiol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Viibryd | Vilazodone Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $909.76 · 49 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FANAPT, FARXIGA, HETLIOZ, Korlym, LEQVIO, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error